Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Pharmavan

    • Home
    • Pharmavan
Company Deals

Pharmavan and Kefeng Changjian Sign Pact to Accelerate SPT-07A Development

Fineline Cube Mar 15, 2025

Suzhou Pharmavan Co., Ltd. has announced plans to enter into a cooperation agreement with Sichuan...

Recent updates

  • Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation
  • Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
  • Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial
  • Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment
  • InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.